Targeting Mitochondrial Dysfunction
For our lead product, Imeglimin, a New Drug Application was submitted in Japan by Sumitomo Dainippon Pharma in July 2020. Imeglimin has successfully completed Phase 2 development in the U.S. and EU. PXL770 and PXL065 are in mid-stage development for NASH. We are also evaluating our AMPK activation and TZD platforms for other chronic and rare metabolic diseases.
View Our Candidates
Innovative Pipeline of First-In-Class Products
Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.
View Pipeline
Backed by Strong Leadership
Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.
Meet Our Team
Latest News
Poxel Presents Imeglimin Phase 3 TIMES Results and PXL770 Preclinical Cardio-Renal Results at the 56th European Association for the Study of Diabetes Annual Meeting
Phase 3 TIMES 2 and TIMES 3 trial results demonstrate that Imeglimin met its primary endpoints and objectives and was observed to exhibit a favorable safety and tolerability profile PXL770, a direct AMPK activator,…
Read this Press Release: Poxel Presents Imeglimin Phase 3 TIMES Results and PXL770 Preclinical Cardio-Renal Results at the 56th European Association for the Study of Diabetes Annual MeetingPoxel Announces Participation at Upcoming Scientific and Investor Conferences
LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and…
Read this Press Release: Poxel Announces Participation at Upcoming Scientific and Investor ConferencesPoxel Reports Financial Results for First Half 2020 and Provides a Corporate Update
Strengthened financial position during H1 2020 with drawdown of IPF loan of EUR 10 million and a capital raise of EUR 17.7 million Imeglimin New Drug Application in Japan (J-NDA) was submitted for the treatment of…
Read this Press Release: Poxel Reports Financial Results for First Half 2020 and Provides a Corporate Update
